And when chatbots get stressed out, they are less likely to be useful in therapeutic settings with people. The bot’s anxiety ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.

Australian doctors who prescribe weight-loss drugs such as Ozempic should be obliged to refer the patient to dieticians at the same time, the nutrition industry's peak body says. Any prescription of ...

To know how much Ozempic (or a similar medication) will cost you, it’s important to know if your medical insurance will cover ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...